Pharmaceutical Company - Publications - Faculty & Research - Harvard Business School

Filter Results: (422)

Filter Results: (422)

Show Results For

← Page 5 of 422 Results →

Sort by

Are you looking for?

→Search All HBS Web

May 2014
Article

Right Up the Middle: How Israeli Firms Go Global

By: Jonathan Friedrich, Amit Noam and Elie Ofek

The article considers international business enterprises based in Israel and how they successfully expanded from their origins as small businesses. A common technique of those companies in which they focused on market entry in other countries whose markets were too... View Details

Keywords: Globalized Firms and Management; Israel

Find at Harvard

May 2025
Case

Daiichi Sankyo: Steering a Global Organization

By: Tiona Zuzul, Amy C. Edmondson and Cat Huang

In the spring of 2023, Sunao Manabe, CEO of Daiichi Sankyo, reflected on a pivotal decision. A large Western pharmaceutical company had made a bid to partner with Daiichi Sankyo to develop the next three products in its oncology pipeline. Daiichi Sankyo, a 125-year old... View Details

Keywords: Strategy; Culture Change; Decision-making; Leadership; Culture; Innovation; Psychological Safety

January 2011 (Revised January 2012)
Supplement

The Case of the Unidentified Healthcare Companies2010 (CW)

By: Richard M.J. Bohmer, Ethan S Bernstein, Margarita Krivitski and Srinidhi Reddy

This case presents financial statements and selected rations for 14 unidentified healthcare organizations and asks that each set of financial information be matched with one of the following healthcare companies: a biotechnology firm, a community nursing company, a... View Details

Keywords: Financial Statements; Financial Management; Health Care and Treatment; Biotechnology Industry; Health Industry

January 2011 (Revised January 2012)
Case

The Case of the Unidentified Healthcare Companies2010

By: Richard Bohmer, Ethan Bernstein, Margarita Krivitski and Srinidhi Reddy

This case presents financial statements and selected ratios for 14 unidentified healthcare organizations and asks that each set of financial information be matched with one of the following healthcare companies: a biotechnology firm, a community nursing company, a... View Details

Keywords: Financial Reporting; Financial Statements; Health Care and Treatment; Health Industry

September 2014 (Revised February 2015)
Case

Pfizer and AstraZeneca: Marketing an Acquisition (A)

By: John A. Quelch and James Weber

In 2014, Pfizer proposed a friendly acquisition of AstraZeneca, but the AstraZeneca board resisted over price and strategy concerns. Was this good for pharmaceutical consumers? Pfizer, like pharmaceutical companies in general, faced difficulties in growing sales due to... View Details

Keywords: Health Care Policy; Mergers And Acquisitions; Marketing; Government Relations; Crisis Management; Decision Making; Growth and Development; Management; Markets; Strategy; Pharmaceutical Industry; United Kingdom; United States

September 1993
Supplement

Manufacturing at ALZA: The Right Prescription? (B)

By: Dorothy A. Leonard

ALZA, a drug delivery company, must decide what and for whom to manufacture. In the past, it has licensed to pharmaceutical companies its patented system for the slow release of drugs into the human system. Therefore the company has little experience in choice of drug... View Details

Keywords: Experience and Expertise; Decision Choices and Conditions; Patents; Production; Pharmaceutical Industry; Pharmaceutical Industry

Find at Harvard

March 1994 (Revised March 1995)
Case

Astra/Merck Group

By: Frank V. Cespedes and Marie Bell

Astra/Merck (A/M), originally a joint venture of AB Astra and Merck & Co., is preparing to be an independent company in 1993. Since the company does not engage in basic research and development of drugs, it is essentially a distribution organization. Fundamental to... View Details

Keywords: Cost vs Benefits; Marketing Strategy; Distribution; Performance Evaluation; Research and Development; Risk and Uncertainty; Sales; Competitive Strategy; Pharmaceutical Industry

Find at Harvard

February 2015 (Revised November 2015)
Supplement

Building an Integrated Biopharma Company: Crucell (B)

By: Richard G. Hamermesh, Marianne Van Der Steen and Susan Harmeling

The Crucell (B) case updates events at Crucell since 2009. In September, 2009, Johnson & Johnson acquired 18% of Crucell for $400 million. This investment was part of a business development deal. Subsequently, in 2012, Johnson & Johnson acquired Crucell for $2.8... View Details

Keywords: Biotechnology; Biopharmacy Company; Licensing Agreements In Biopharmacy; Licensing; Human Cell-line Technology; Vaccine; Healthcare Innovation; Global Health; Entrepreneurship; Health Care and Treatment; Acquisition; Innovation and Invention; Pharmaceutical Industry; Pharmaceutical Industry

14 Dec 2020
Research & Ideas

What Does December's Drug-Approval Dash Mean for COVID-19 Vaccines?

Pharmaceutical regulators around the world tend to speed through drug applications in December and before major national holidays, according to new research that might raise questions about COVID-19 vaccines and other treatments under... View Details

Keywords: by Danielle Kost; Pharmaceutical; Pharmaceutical

October 2011 (Revised June 2013)
Case

Novo Nordisk: A Commitment to Sustainability

By: Robert G. Eccles and Michael P. Krzus

The case describes the early commitment of a European pharmaceutical company, Novo Nordisk, to integrated reporting. Novo Nordisk is one of the pioneers of integrated reporting and it emerged out of its commitment to a "Triple Bottom Line approach to managing the... View Details

Keywords: Strategic Planning; Business Ventures; Business or Company Management; Integrated Corporate Reporting; Business Strategy; Pharmaceutical Industry

September 1995
Case

Ares-Serono

By: Michael Y. Yoshino, Jean-Pierre Jeannet and Carin-Isabel Knoop

Ares Serono, a medium-size Swiss pharmaceutical company, is the global leader in the field of fertility drugs. The company has successfully transformed into one of the very few biotech firms in Europe. The case treats a set of major strategic and organizational... View Details

Keywords: Geographic Location; Globalized Firms and Management; Asset Management; Balance and Stability; Expansion; Digital Platforms; Leadership Development; Health Care and Treatment; Transformation; Family Business; Problems and Challenges; Pharmaceutical Industry; Pharmaceutical Industry; Switzerland; Europe

Find at Harvard

October 2016 (Revised February 2017)
Teaching Note

Alvogen

By: Daniel Isenberg, William R. Kerr and Alexis Brownell

Alvogen is an Icelandic pharmaceutical company that makes and sells generic drugs. Founder and CEO Robert Wessman is deciding whether to take on private equity investors willing to buy out all shareholders, merge with a large and publicly-traded US pharmaceutical... View Details

Keywords: Biotechnology; Globalization; Entrepreneurship; Biotechnology Industry

January 2001
Case

Abgenix and the XenoMouse

By: Robert J. Dolan

Abgenix has a unique method for generating antibodies useful in treating a number of diseases, including cancer. In early 2000, the company's cancer has performed very well in animal testing and is moving to early stage human testing. Abgenix must decide whether to... View Details

Keywords: Product Development; Marketing Strategy; Health Testing and Trials; Risk and Uncertainty; Technological Innovation; Innovation Strategy; Science-Based Business; Biotechnology Industry

September 2023 (Revised April 2024)
Case

Atomwise: Strategic Opportunities in AI for Pharma

By: Satish Tadikonda

Abraham Heifets and his co-founder, Izhar Wallach, had founded Atomwise to develop i) an AI engine to transform drug discovery by creating better medicines faster, and ii) a machine learning-based discovery engine that combined the power of convolutional neural... View Details

Keywords: Business Model; Business Startups; AI and Machine Learning; Science-Based Business; Technological Innovation; Pharmaceutical Industry; Pharmaceutical Industry

October 2012
Case

Sirtris Pharmaceuticals: Living Healthier, Longer (Abridged)

By: Toby Stuart and James Weber

Describes a set of key strategic decisions facing the scientific founder and CEO of a promising, early stage bio-pharmaceuticals company. Should the company establish a proposed alliance with a pharmaceutical firm? Should it create a nutraceuticals business in parallel... View Details

Keywords: Business Startups; Decision Choices and Conditions; Entrepreneurship; Growth and Development Strategy; Risk Management; Brands and Branding; Pharmaceutical Industry

March 2008 (Revised June 2008)
Case

Sirtris Pharmaceuticals: Living Healthier, Longer

Describes a set of key strategic decisions facing the scientific founder and CEO of a promising, early stage bio-pharmaceuticals company. Should the company establish a proposed alliance with a pharmaceutical firm? Should it create a nutraceuticals business in parallel... View Details

Keywords: Business Startups; Decision Choices and Conditions; Entrepreneurship; Growth and Development Strategy; Risk Management; Brands and Branding; Pharmaceutical Industry

December 2000 (Revised January 2001)
Background Note

Promise of Functional Foods, The

By: Ray A. Goldberg, Carin-Isabel Knoop and Laure Mougeot Stroock

This case presents a definition of functional foods or nutraceuticals (food or food ingredients that could provide a health benefit beyond the traditional nutrients they contain), a description of some of the major obstacles to their commercialization and... View Details

Keywords: Food; Private Sector; Public Sector; Health; Product Development; Production; Commercialization; Pharmaceutical Industry; Pharmaceutical Industry

Find at Harvard

February 2009 (Revised December 2009)
Case

Merck: Global Health and Access to Medicines

By: V. Kasturi Rangan and Katharine Lee

The case describes the effort of Merck, a global leader in pharmaceuticals, in making available its medicines to the poor. The challenge for the company (or for that matter, any pharmaceutical company) is how to integrate its business strategy with its corporate social... View Details

Keywords: Globalized Firms and Management; Health Care and Treatment; Emerging Markets; Corporate Social Responsibility and Impact; Poverty; Business Strategy; Pharmaceutical Industry

July 2004 (Revised May 2005)
Case

Pfizer's Virtual CIO (Abridged)

By: F. Warren McFarlan and Brian DeLacey

Discusses the IT organization and IT strategy issues facing Pfizer, one of the world's largest pharmaceutical companies. Managing over $1 billion of IT expense, the company has a committee approach for handling all critical IT decisions, an approach that is consistent... View Details

Keywords: Decision Making; Cost Management; Organizational Culture; Strategy; Information Technology; Pharmaceutical Industry

Find at Harvard

September 1990 (Revised January 1992)
Case

Eli Lilly and Co. (A): Globalization

By: Michael Y. Yoshino

Examines the changes taking place in Eli Lilly in response to the globalization of the pharmaceuticals industry. Identifies the steps taken by management, problems currently faced, and challenges for the future. Allows examination of the process of implementing a... View Details

Keywords: Change; Globalization; Global Strategy; Business or Company Management; Problems and Challenges; Perspective; Pharmaceutical Industry

←
5
6
…
21
22
→